Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of MK-1403 Formulations in Healthy Adults
NCT07677163Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2026
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 1 trial of MK-1403 in atherosclerotic cardiovascular disease (ASCVD) (3 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants Who Experience an Adverse Event at 4 weeks, Number of Participants Who Discontinue the Study Intervention Due to an AE at 2 weeks and 3 more. Started Aug 2026; status: completed.
02
Drugs
MK-1403
03
Conditions
atherosclerotic cardiovascular disease (ASCVD)
Beyond the preview
Go deeper on NCT07677163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07677163.